This document is an excerpt from the EUR-Lex website
Life sciences and biotechnology
Life sciences and biotechnology
Life sciences and biotechnology
This summary has been archived and will not be updated, because the summarised document is no longer in force or does not reflect the current situation.
Life sciences and biotechnology
Helping the European Union to harness the life sciences and biotechnology in many areas such as health care, agriculture, food, industrial uses and the environment in order to create a sustainable, knowledge-based economy. This is the aim of the various acts in this field adopted by the European Commission over the last few years. For Europe, life sciences and biotechnology represent both a challenge and a major potential to be harnessed. A potential which the Commission aims to develop by means of a European strategy. This document summarises the main aspects of that strategy (the basic idea, the challenges, the action planned, ethical aspects, etc).
Communication from the Commission to the Council, the European Parliament, the Economic and Social Committee and the Committee of the Regions of 23 January 2002: "Life sciences and biotechnology - A Strategy for Europe" [COM(2002) 27 final - Official Journal C 55 of 2.3.2002].
Biotechnology is a technique which, by means of genetic manipulation, produces biological molecules or transgenic organisms for industrial, agricultural, pharmaceutical or chemical applications, etc.
The life sciences raise important policy and social issues and have prompted wide public debate. A revolution is taking place in the biotechnology knowledge-base, opening the way to new applications in the areas of health care, agriculture, food production and environmental protection.
Major scientific and technological advances have been made in life sciences and biotechnology over the last few years. In response, in January 2002 the European Commission adopted a strategy for Europe to devise sustainable and responsible policies to deal with the following three major issues:
The strategy is divided into two sections:
It reflects the importance which the European Council attaches to the life sciences. It proposes a comprehensive roadmap up to 2010 and puts the sector at the forefront of those frontier technologies which are helping the European Union to meet the Lisbon objectives.
The potential of life sciences and biotechnology
Life sciences and biotechnology are widely regarded as being among the most promising frontier technologies for the coming decades.
In the health care sector, biotechnology already permits safer and more ethical production of an increasing number of drugs and medical services. Stem cell research offers the prospect of replacement tissues and organs to treat degenerative diseases, Alzheimer's disease and Parkinson's disease, etc. It also opens up prospects for quality-of-life improvement through innovative medical applications.
In the agri-food sector, biotechnology has the potential to improve the quality of foodstuffs and animal feed to help prevent disease and reduce health risks. Plant genome research is a key area. In this context, the size of the world's area under genetically modified crops (GMOs) has nearly doubled.
In the case of non-food uses for crops, biotechnology helps to improve the use of industrial raw materials for the energy transformation industry and the pharmaceutical industry. The modifications under development include alterations to carbohydrates, oils, fats, proteins and fibres. Similarly, biomass could provide alternative sources of energy, with both liquid and solid biofuels such as biodiesel and bioethanol.
From an environmental point of view, biotechnology offers new ways to protect and improve the environment, especially air, soil, water and waste. Research focuses on the development of cleaner industrial products and processes and on more sustainable agricultural practices.
In the context of the revised Lisbon strategy, the life sciences and biotechnology sector should have a role to play. As the latest progress report points out, over the coming decades it should:
Harnessing the potential
The European strategy for the life sciences and biotechnology identifies the following strategic priorities:
Europe's competitiveness should be enhanced through three main pillars for action:
Biotechnology focuses on solving specific problems. The strategy pays special attention to building up the competitiveness of European industry by improving the potential to create small and medium-sized enterprises (SMEs) whose activity is based on research and the spirit of enterprise. These new industries, founded on scientific knowledge, are a source of industrial competitiveness, technological innovation, investment opportunities and job creation.
Ethical and social implications
The development and application of life sciences and biotechnology raise fundamental ethical questions such as the definition and the nature of human beings and the use and supervision of genetic information.
In addition, the life sciences and biotechnology have attracted much attention from the general public and prompted serious debate. The dialogue should be open, in-depth, well-informed and structured in order to provide better information and promote mutual understanding. It is therefore of key importance to promote information and dialogue to help the public and stakeholders to better understand and appreciate these complex issues and to develop methods and criteria for weighing the benefits against disadvantages or risks.
The public authorities, economic operators and the scientific community should strive to communicate the relevant facts and facilitate an understanding of the key questions in a context of international cooperation.
Steps to be taken: action plan
The objective of the action plan is to set up a coherent policy framework aimed at promoting the creation of conditions favourable to the development of biotechnology in Europe and to collaboration between the Member States and private individuals or organisations. There are four types of action:
Progress reports and outlook
To take stock of the progress being made under this strategy at regular intervals, the Commission has adopted three progress reports since 2002. In these, the Commission reviews not just the progress made but also the hold-ups encountered in some areas. The three reports set out the results achieved in terms of policy development and implementation on the ground, and address new emerging issues. Where possible, they also look into the areas covered by the roadmap.
For the mid-term review of current strategy (at the European Council meeting in spring 2007), the European Commission has made an in-depth evaluation of the progress achieved since 2002 and looked at the overall role of life sciences and biotechnology in European society. These two initiatives are based in particular on:
The EU has a substantial research potential in the area of biotechnology. Society needs to reap the expected benefits in terms of growth and job creation. The Fifth (1998-2002) and Sixth (2002-2006) Framework Programmes provided researchers, businessmen, industrialists and financiers with the means. Life sciences and biotechnology are also a global reality and are vital for generating knowledge-based dynamic and innovative economies. The success of any knowledge-based economy also rests upon the generation, dissemination and application of new knowledge. However, European investment in research and development is lagging behind that of the United States. The Commission aims to restore European leadership in the life sciences and biotechnology. The Sixth Framework Programme for research (2002-2006) makes this area a priority, providing a solid platform for constructing a European research area in collaboration with the Member States.
Communication from the Commission to the Council, the European Parliament, the European Economic and Social Committee and the Committee of the Regions on the mid-term review of the Strategy on Life Sciences and Biotechnology [COM(2007) 175 final - Not published in the Official Journal].
In this document the Commission underlines the effectiveness of the life science and biotechnology strategy, which it intends to complete as scheduled (2011).
The main results highlighted for the period ended (2002-2006) are:
By contrast, the results as regards promotion and development of innovation in biotechnology are less striking. In this sector, small and medium-sized enterprises (SMEs) are still suffering from the lack of a Community framework (patents), low investment levels and poor cooperation between the academic world and finance.
The Commission identifies five priority areas of action for the strategy:
The document also describes a number of modern life science and biotechnology applications, with information on their impact in areas such as industry, the economy, the environment and healthcare.
Report from the Commission to the European Parliament, the Council, the Committee of the Regions and the European Economic and Social Committee of 29 June 2005 "Life sciences and biotechnology - A strategy for Europe" Third progress report and future orientations [COM(2005) 286 final - Not published in the Official Journal].
Report from the Commission to the European Parliament, the Council and the European Economic and Social Committee of 7 April 2004 "Life sciences and biotechnology - A strategy for Europe" Second progress report and future orientations [COM(2004) 250 final - Not published in the Official Journal].
Communication from the Commission to the European Parliament, the Council and the European Economic and Social Committee of 5 March 2003 "Life sciences and biotechnology - A strategy for Europe" Progress report and future orientations [COM(2003) 96 final - Not published in the Official Journal].
Communication from the Commission to the Council, the European Parliament, the Economic and Social Committee and the Committee of the Regions of 4 December 2001 "Science and Society - Action Plan" [COM(2001) 714 final - Not published in the Official Journal].
Communication from the Commission of 4 September 2001 "Towards a strategic vision of life sciences and biotechnology - Consultation document" [COM(2001) 454 final - Not published in the Official Journal].
Last updated: 04.03.2008